Celebrity pitch-folks may not be worth the money, study finds

Tracy Staton Celebrities are making more and more appearances in pharma's DTC advertising. But do they help meds score with patients the same way they help sell consumer goods? FiercePharma ...

Bayer’s Nexavar misses another study endpoint, this time for breast cancer

Eric Palmer Nexavar, the blockbuster cancer drug sold by Bayer and Onyx Pharmaceuticals, has failed again in a trial for a new indication.  FiercePharma News

Regeneron, Sanofi herald a blockbuster contender with groundbreaking study

John Carroll If you want to understand why Regeneron R&D chief George Yancopolous gets a king's ransom in annual compensation, you need look no further than the Phase IIb data ...

Study: Med students cozy with pharma reps more likely to dole out branded drugs

Emily Wasserman Doctors aren't the only ones to fall prey to free lunches and fuzzy promotional talks. Medical students who spend more time with& pharma reps are more likely ...

AbbVie’s leukemia drug program continues to wow analysts in early study

John Carroll AbbVie's experimental leukemia drug ABT-199 is continuing to wow analysts with some stellar early-stage data. At the interim point of a Phase Ib study, ABT-199/GDC-0199 ...

Isis surges on promising head-to-head thrombosis drug study

John Carroll Shares of Isis Pharmaceuticals surged 9% this morning as the Carlsbad, CA-based antisense drug developer posted positive outcomes for a head-to-head Phase II study comparing ...

AstraZeneca rushes immuno-oncology star into PhIII lung cancer study

John Carroll Anxious to fight off Pfizer’s $ 106 billion marriage proposal, AstraZeneca’s research team has rushed its high-profile immuno-oncology drug into a late-stage ...

Novartis hopes new COPD study data will draw patients from Glaxo’s Advair

Carly Helfand Novartis' generic of Advair in Europe is already a thorn in GlaxoSmithKline's side when it comes to sales of the declining blockbuster. Now, it says, another of ...

Docs that just say no to drug samples slash brand prescribing big-time, study finds

Tracy Staton A new JAMA Dermatology study shows a huge difference in brand-name scripts written by physicians who turn down drug samples–a 62-percentage-point difference, ...

Critics knock JAMA study linking testosterone drugs to cardio risks

Carly Helfand A study the FDA has cited as a reason to investigate the cardiovascular safety of testosterone drugs has come under heavy fire from critics. Physicians and researchers ...

Study: Most Workers Satisfied With Pay-Benefits Balance

barbara.lempert New Research from EBRI: Most Workers Satisfied With Pay-Benefits Balance; Health Insurance Remains Key Job-Choice Factor   WASHINGTON, DC—Most workers are satisfied ...

Continuing Medical Education Deserves More Scrutiny: Study

esilverman At a time when increasing scrutiny is applied to funding for continuing medical education, a new study notes that relatively little is known about medical communications ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS